Noradrenalina Labesfal (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Noradrenalina Labesfal, is an adrenergic agonist presented as an intravenous solution for intravenous use. It is employed to raise blood pressure in patients with hypotension, support circulation during cardiac arrest, and improve vascular tone in septic shock. GNH USA supplies Noradrenalina Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Noradrenalina Labesfal acts as a potent vasopressor in critical‑care settings, targeting severe circulatory failure. - Hypotension: restores arterial pressure by inducing vasoconstriction. - Cardiac arrest: provides immediate circulatory support to maintain perfusion during resuscitation. - Septic shock: increases systemic vascular resistance to counteract profound vasodilation.

Adverse reactions may occur with intravenous noradrenaline administration.

Common Side Effects: - Headache: mild to moderate intensity. - Tachycardia: elevated heart rate due to beta‑1 stimulation. - Palpitations: sensation of rapid or irregular heartbeat. - Peripheral ischemia: reduced blood flow to extremities. - Nausea: occasional gastrointestinal discomfort. - Anxiety: heightened nervousness or restlessness.

Serious or Rare Side Effects: - Arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced oxygen supply to heart muscle. - Severe hypertension: abrupt, dangerous rise in blood pressure. - Tissue necrosis: local injury at infusion site if extravasation occurs.

Clinicians should observe specific safety measures when using Noradrenalina Labesfal. - Monitoring: continuous blood pressure and cardiac rhythm monitoring is required. - Dose titration: adjust infusion rate based on hemodynamic response. - Extravasation risk: avoid infiltration; stop infusion immediately if leakage suspected. - Contraindications: avoid in patients with uncorrected pheochromocytoma or severe ventricular dysfunction. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Noradrenaline may interact with several agents, altering its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may blunt the desired increase in heart rate and contractility. - MAO inhibitors: can potentiate hypertensive effects. - Tricyclic antidepressants: increase risk of severe hypertension.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitroglycerin): may require higher noradrenaline doses. - Calcium channel blockers: can affect vascular tone and heart rate. - Diuretics: may influence intravascular volume and response to vasopressor therapy.